 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Edge Therapeutics, Inc. new article content ...
| Industry | Pharmaceutical industry |
|---|---|
| Founded | 2009 |
| Headquarters | Newark, NJ, U.S. |
Key people | Brian Leuthner (President & CEO) R Loch Macdonald, MD, PhD (Chief Scientific Officer) |
| Website | http://www.edgetherapeutics.com |
Edge Therapeutics, Inc. is a specialty pharmaceutical company established in 2009 and headquartered in Newark, NJ. Edge Therapeutics, Inc. focuses on preventative treatment for secondary complications following brain injury. Edge Therapeutics, Inc. is currently developing 4 drugs. NimoGel, Edge's lead product, is being developed to prevent secondary strokes after subarachnoid hemorrhage (SAH), which is caused by bleeding into the fluid around the brain. NimoGel combines a generic calcium channel blocker nimodipine, formulated in a biodegradable polymer carrier composed of FDA-approved materials.
In 2009 Edge was awarded a $500,000 grant from the New Jersey Commission on Science and Technology Edison Innovation Fund and in 2010 Edge received $100,000 in funding from the New Jersey Economic Development Authority.